Help us answer questions that your doctors and the CMT Research Community aren’t too sure about.

by | Aug 19, 2014 | 1 comment


Dr. Sean Ekins is Principal Investigator of GRIN, which is now in its second year. Dr. Ekins is a clinical pharmacologist by training with over 18 years of experience in pre-clinical drug development, toxicity and computational drug discovery research in large Pharma (Lilly, Pfizer), biotech, informatics software companies (GeneGo, Collaborative Drug Discovery, Inc.) and start up drug companies (Phoenix Nest).

As Chief Science Officer of HNF, it is his responsibility to oversee the success of our TRIAD research program in which we fund translational research (pre-clinical and clinical),  projects. HNF’s goal is to expedite the research process from bench to bedside. While there has been a considerable amount of research on CMT there is urgency to provide the thousands of patients progressing rapidly, with a therapeutic that offers a benefit to them.

As we continue to translate our research and partner with various academics, industry leaders, government and not-for-profit stakeholders that are aligned with HNF’s mission, your participation is an intricate and an important part of the process. Please Join us and contribute to GRIN, our patient registry, which will help us in our quest to cure CMT.

Learn more on this topic

Related Blog Posts

Calling Everyone With CMT/IN

HNF has launched a new Patient-Reported Research Study to advance therapies for CMT and inherited neuropathies (IN) in an effort to collect comprehensive data for a better understanding of the disease.

Join the conversation

Leave a Comment

1 Comment

  1. J Brian C Saunders

    Could you please give me a definition of CMT type 2 axonal
    Thanking you in anticipation



Submit a Comment

Your email address will not be published. Required fields are marked *


Join for notifications on events, campaigns, & news